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CLINICAL TRIALS AND OBSERVATIONS
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Patients with core binding factor acute
myeloid leukemia (CBF-AML) benefit from
more intensive chemotherapy, but whether
both the t(8;21) and inv(16)/t (16;16) sub-
types requires intensification remained
to be determined. In the 2 successive
studies (AML-BFM-1998 and AML-BFM-
2004), 220 CBF-AML patients were treated
using the same chemotherapy backbone,
whereby reinduction with high-dose cy-
tarabine and mitoxantrone (HAM) was
scheduled for these cohorts only in study
AML-BFM-1998 but not in AML-BFM-2004
against the background to minimize over-
treatment. Five-year overall survival (OS)
and event-free survival (EFS) were signifi-
cantly higher and the cumulative inci-
dence of relapse (CIR) lower in t(8;21)
patients treated with HAM (n  78) com-
pared with without HAM (n  53): OS
92%  3% versus 80%  6%, plogrank0.047,
EFS 84%  4% versus 59%  7%,
plogrank0.001, and CIR 14%  4% versus
34%  7%, p(gray)0.006. These differences
were not seen for inv(16) (n  43 and 46,
respectively): OS 93%  4% versus
94%  4%, EFS 75%  7% versus
71%  9% and CIR 15%  6% versus
23%  8% (not significant). The subtype
t(8;21), but not inv(16), was an indepen-
dent predictor of worse outcome without
HAM reinduction. Based on our data, a
5-year OS of > 90% can be expected for
CBF-AML, when stratifying t(8;21), but
not inv(16), patients to high-risk chemo-
therapy, including HAM reinduction.
(Blood. 2011;118(20):5409-5415)
Introduction
Core binding factor (CBF) acute myeloid leukemia (AML)
include 2 major subtypes with the translocation (8;21)(q22;q22)
[ t(8;21)] and inversion of chromosome 16 (p13q22) and its
variant t(16;16)(p13;q22) [ inv(16)] that occur predominantly in
younger patients and are associated with a relative favorable
prognosis. Overall survival (OS) rates have improved after intensi-
fication of the treatment by different approaches, to reach between
60% and 70% in adults and 80% in children.1-5 The incidence of
t(8;21) is 12% to 14% in children and adolescents3,4,6 and  7% in
adults with AML younger than 60 years.2,7 Inversion 16 is less
frequent: children 7% to 9%3,4 and adults 4%.2,7
In particular, intensive postremission chemotherapy with high-
dose cytarabine (HDAC) improved prognosis in patients with CBF
leukemia.8,9 More recent studies indicate that CBF-AML with
t(8;21) may be associated with less favorable prognosis than with
inv(16).9,10 The question whether patients with both CBF-AML
subtypes benefit from treatment intensification and which treatment
strategy is optimal is still inconclusively addressed.5
The evolution of the AML treatment strategy in 2 subsequent
pediatric trials from the AML-BFM study group now provides the
opportunity to address the importance of a second induction with
HDAC and mitoxantrone (HAM) for these CBF-AML subtypes.
Based on the superior outcome with an intensified second
induction with HAM in the AML-BFM 93 study, which was
introduced for high-risk patients only, excluding all patients with
t(8;21) and inv(16),11 HAM treatment was also introduced for
patients with CBF-AML in the subsequent AML-BFM-1998 study,
given its tolerable acute toxicity profile. However, based on a
preliminary analysis that failed to show a benefit of treatment
intensification for this AML subtype and with a concern to avoid
toxicity, second induction with HAM was omitted in the current
AML-BFM-2004 trial for CBF-AML patients (Figure 1). Here we
report that reduction of treatment intensity by omission of HAM
resulted in an unexpected and marked decrease in event-free
survival (EFS) and OS in patients with t(8;21), but not in patients
with inv(16), providing compelling evidence to suggest that the
2 subtypes of CBF-AML should be considered separately and that
the addition of HAM is beneficial for patients with t(8,21) in the
context of the AML-BFM chemotherapy backbone.
Methods
Patients
Between July 1998 and December 2009, 1280 AML patients younger than
18 years were enrolled in studies AML-BFM-1998 and AML-BFM-2004.
Of these, 131 (10%) presented with t(8;21) or the molecular genetic
equivalent AML1/ETO alone, and 91 (7%) with inv(16) or the molecular
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genetic equivalent CBFB-MYH11 alone. Two patients were excluded from
the analysis because they died before the second therapy course. Patients
treated in study AML-BFM-1998 and in the AML-BFM-1998 interim phase
(amendment to study AML-BFM-1998 implemented after closure of study
AML-BFM-1998 (July 2003 until March 2004) are summarized as
AML-BFM-1998 (n  110) in the following analysis. Their data were
compared with those of study AML-BFM-2004 (n  110). In study
AML-BFM-1998, a second induction with HAM was scheduled, but
neither in the interim phase nor in study AML-BFM-2004. For the main
analysis, results were compared according to treatment (HAM vs no HAM)
because, in both studies, treatment differed in some patients: study
AML-BFM-1998, 15 patients without HAM from the AML-BFM-1998
interim phase; study AML-BFM-2004, 9 patients with  5% BM blasts on
day 15, 2 patients with FLT-ITD, and 15 other patients (9 with  5% BM
blasts on day 28) with HAM. The study was approved by the ethical
committee of the University of Muenster.
The studies were performed in Germany, Austria, Switzerland, and the
Czech Republic. Written informed consent from patients, parents, or
guardians was obtained at study entry in accordance with the Declaration of
Helsinki.
Central review of BM morphology and cytogenetics was performed.
Comprehensive cytogenetic data from 119 of 131 (91%) of the patients with
t(8;21) and 79 of 89 (89%) with inv(16) were available. Cytogenetic
analysis was performed as previously described.4 Routine testing for
FLT3-ITD at initial diagnosis has been performed since study AML-BFM-
2004, when stratification to the standard risk group was, among others,
based on negativity for FLT3-ITD.
Treatment plan
All patients were treated according to regimens AML-BFM-1998, AML-
BFM-1998-Interim, or AML-BFM-2004,12,13 which were similar for most
parts (Figure 1).12 The AML-BFM-1998 protocol, with the exception of the
AML-BFM-1998-Interim phase, included HAM after induction with cytar-
abine, idarubicin, and etoposide (AIE) for all patients. In AML-BFM-2004,
HAM was exclusively given to high-risk patients after induction with AIE
or with cytarabine, liposomal daunorubicin, and etoposide. Standard risk,
including t(8;21) and inv(16), patients with BM blasts  5% on day 15,
were restratified to the high-risk group and treated with HAM. After first
induction (study AML-BFM-2004) or after HAM (study AML-BFM-1998),
2 additional short cycles with medium (0.5 g/m2) and HDAC (1-3 g/m2) and
anthracyclines were administered (Figure 1). Intensification and mainte-
nance regimens were similar during both study periods, with no indication
for allogeneic hematopoietic stem cell transplantation in CR1 in standard-
risk patients.13 Intrathecal cytarabine was given 11 times following
age-dependent dosage regimens.
Definition and statistics
Risk classification was based on morphology, cytogenetics, molecular
genetics, and response to treatment: Standard risk indicates French-
American-British (FAB) M1/2 with Auer rods, FAB M4 with atypical
eosinophils (M4Eo), FAB M3 and/or favorable cytogenetics, such as t(8;21)
and/or AML1-ETO, t(15;17), and/or PML-RARA and inv(16) or t(16;16)
and/or CBFB/MYH1, if there was no persistence of BM blasts ( 5%) on
day 15 or FLT3-ITD positivity (FAB M3 excluded). All others were
classified as high-risk patients. Since study AML-BFM-2004, FLT3-ITD
mutation analysis was part of the risk group stratification because the
negative impact of this mutation was found to be in general a strong and
independent adverse prognostic factor in pediatric AML.14
CR was defined according to the CALGB criteria15 and needed to be
achieved at the end of intensification treatment. EFS was calculated from
the date of diagnosis to last follow-up or first event (failure to achieve
remission, relapse, secondary malignancy, or death of any cause). Survival
was calculated from the date of diagnosis to death of any cause or last
follow-up. Probabilities of survival were estimated using the Kaplan-Meier
method with SEs according to Greenwood16 and compared with the
log-rank test. Cumulative incidence functions of relapse and secondary
malignancy were constructed by the method of Kalbfleisch and Prentice.16
Functions were compared with Gray’s test. Toxicity was assessed according
to the NCI Common Toxicity Criteria Version 2.0 (www.ctep.cancer.gov/
reporting).
Univariate analysis was conducted by the Wilcoxon test for quantitative
variables and Fisher exact test for qualitative variables. When frequencies
were sufficiently large, 2 statistics were used. Computations were per-
formed using SAS (Statistical Analysis System Version 9.1; SAS Institute).
Results
Patient characteristics
Table 1 shows patient characteristics corresponding to the cytoge-
netic subgroups and to the treatment with or without HAM.
Translocation (8;21) patients were older by trend (see interquartile
range) than inv(16) patients (P  .06, Table 1). Median WBC
count at diagnosis was significantly higher in inv(16) patients
(P  .001). Translocation (8;21)/AML1/ETO was associated with
the FAB subtype M2 with Auer rods (101 of 131, 77%) and
inv(16)/CBFB-MYH11 with FAB subtype M4Eo (85 of 89, 96%).
Eighteen of 127 t(8;21) patients (14%), but only 2 of 83 (2%) of
those with inv(16) presented with more than 5% BM blasts on day
15 (P  .001). Initial CNS involvement occurred more frequently
among inv(16) patients (20 of 86, 23%) than among t(8;21) patients
(9 of 131, 7%, P  .0005). Seventeen of the t(8;21) patients
presented with orbital involvement, 3 of them combined with a
CNS manifestation, in contrast to inv(16) patients (only 2 with
orbital involvement, one combined in the CNS), whereas other
extramedullary leukemia was found equally often in both groups.
For 37 of 119 patients (31%), t(8;21) was the sole aberration,
whereas 82 of 119 patients (69%) also harbored secondary
cytogenetic abnormalities, such as loss of sex chromosomes (LOS;
n  57 of 119, 48%, Table 2). In 12 patients, only the AML1/ETO
rearrangement was examined. In 26 of 79 (33%) patients with
inv(16), additional aberrations occurred; the most common was
trisomy 22 (11 of 79, 14%).
In both studies, patient characteristics, including cytogenetic
findings, were comparable in the respective groups with t(8;21) and
inv(16) (supplemental Table 1, available on the Blood Web site; see
the Supplemental Materials link at the top of the online article) and
in the corresponding treatment groups with or without HAM
(Tables 1 and 2).
Figure 1. Treatment schedules of studies AML-BFM-1998 and AML-BFM-2004 in
standard-risk patients. Induction: AIE indicates cytarabine/idarubicin/etoposide or
randomized with ADxE; and ADxE, cytarabine/liposomal daunorubicin/etoposide.
Second induction: HAM indicates high-dose cytarabine [3 g/m2]/mitoxantrone. Con-
solidation: AI indicates cytarabine [0.5 g/m2]/idarubicin; and hAM, high-dose cytara-
bine [1 g/m2]/mitoxantrone. Intensification: HAE indicates high-dose cytarabine
[3 g/m2]/etoposide; and CNS-RT, cranial irradiation.
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Study periods
For t(8;21) patients treated in study AML-BFM-1998, EFS was
significantly higher compared with study 2004 (81%  5% vs
66%  6%, plogrank  0.046), whereas the cumulative incidence of
relapse (CIR) was lower (16%  5% vs 28%  6%, p(gray)  0.009;
supplemental Figure 1A-C). This was different for patients with
inv(16) (EFS 74%  7% vs 74  9%, plogrank  0.98, CIR
14%  5% vs 26%  9%, p(Gray)  0.26; supplemental Table 2).
Treatment with or without HAM
Comparing results after treatment with or without HAM (see
“Patients”), the differences in outcome of t(8;21) patients were
even more obvious. Five-year survival was significantly higher in
the cohort who received HAM (n  78) than in the one without
HAM (n  53; 92%  3% vs 80%  6%, plogrank  0.047; Figure
2A). EFS data strongly confirmed these observations (84%  4%
vs 59%  7%, plogrank  0.001; Figure 3A). The CIR was also
lower for patients who received HAM (14%  4% vs 34%  7%,
p(gray)  0.006; Figure 4A). This was different for patients with
inv(16) (survival, 93%  4% vs 94  4; EFS: 75%  7% vs
71%  9%; and CIR 15%  6% vs 23%  8%; all P values not
significant, Figures 2B, 3B, and 4B).
In study AML-BFM-2004, there were 3 nonresponders among
the t(8;21) patients (in the “no-HAM” group). Three patients died
in CR, one in the no-HAM and 2 in the HAM group. All inv(16)
patients reached a CR. Two patients died in remission after HAM
because of severe infections (Table 3).
Table 1. Initial basic data of patients with t(8;21) and inv(16) treated with or without HAM
t(8;21) inv(16)
Total t(8;21) Total inv(16) P (2)HAM No HAM P (2) HAM No HAM P (2)
No. of patients 78 53 43 46 131 89
Median age, y 9.7 11.6 .22 11.6 9.8 .65 10.5 10.1 .06
Q1-Q3 6.5-14.0 8.8-13.9 4.9-13.0 2.8-13.8 7.6-14.0 3.3-13.6
Leukocytes,  109L, median 9100 11 020 .36 34 900 50 300 .15 10 400 41 900  .001
Q1-Q3 5600-17 050 5700-22 500 21 400-108,000 15 000-18 200 5600-21 000 19 735-93 950
Sex, no. (%)
Male 44 (56) 27 (52) .54 20 (47) 25 (54) .46 71 (54) 45 (51) .60
Female 34 (44) 26 (48) 23 (53) 21 (46) 60 (46) 44 (49)
CNS involvement, no. (%) 5 (6) 4 (8) .80 14 (35) 6 (13) .016 9 (7) 20 (23) .001
Extramedullary organ
involvement, no. (%) 19 (24) 12 (23) .90 11 (26) 11 (24) .81 31 (23) 22 (25) .82
Blasts day 15  5%,* no. (%) 18 (23) 0 (0)  .001 2 (5) 0 (0) .14 18 (14) 2 (2) .005
Cytogenetic data, no. (%) 71 (91) 48 (91) 1.00 43 (100) 36 (78) 119 (91) 79 (89)
Molecular genetic only, no. (%) 7 (9) 5 (9) 1.00 0 (0) 10 (22) 12 (9) 10 (11)
Risk groups, no. (%)
SR 54 (69) 52 (98)  .001 37 (86) 44 (96) .11 106 (81) 81 (91) .04
HR† 24 (31) 1 (2) 6 (14) 2 (4) 25 (19) 8 (9)
*Patients with data.
†Restratification to high-risk (HR), because of blasts  5% on day 15 or FLT3-ITD positivity.
Table 2. Most common cytogenetic data of 119 patients with t(8;21)*
and 79 patients with inv(16) treated with or without HAM
With HAM No HAM
P
Total
n % N % n %
t(8;21) 	solely
 19 27 18 4 .31 37 31
t(8;21) Y† 22 31 11 23 .37 33 28
t(8;21) X† 16 22 8 17 .47 24 20
t(8;21) del(9q) † 5 7 8 17 .10 13 11
t(8;21) 8† 6 9 3 6 .66 9 8
inv(16) 	solely
 28 65 25 69 .68 53 65
inv(16) 22† 5 12 6 17 .52 11 14
inv(16)  other‡ 10 23 5 14 .29 15 19
*Of 119 patients with data on cytogenetics, 17 patients had other secondary
aberrations, including multiple nomination.
†As a sole aberration or with additional aberrations.
‡Further aberrations.
Figure 2. Estimated probability of 5-year survival in patients. (A) Patients with
t(8;21). (B) Patients with inv(16). Treated with or without HAM.
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After relapse
Survival rates of patients who had a relapse are generally better in
CBF-AML patients than in other AML cohorts.17 The former were
comparable in studies AML-BFM-1998 and AML-BFM-2004
(50%  16% vs 64%  13%, plogrank  0.57) and also for patients
who did or did not receive HAM (60%  16% vs 57%  13%,
plogrank  0.85). This was also seen in inv(16) patients: studies
AML-BFM-1998 and AML-BFM-2004 (66%  19% vs
85%  13%, plogrank  0.35), with or without HAM (83%  15%
vs 73%  17%, plogrank  0.66). These results also imply that
pediatric CBF-AML patients are salvageable after first relapse.
BM blast count on day 15
Early response to induction treatment evaluated by analysis of day
15 BM was one of the most important prognostic factors for
AML.18,19 In study AML-BFM-1998, EFS results were similar for
t(8;21) patients with BM blasts  5% or  5% on day 15 (all of
them treated with HAM; 81%  5% vs 78%  14%,
plogrank  0.89). However, in study AML-BFM-2004, there was
a marked difference in EFS in favor of patients with  5% BM
blasts on day 15 (ie, in favor of exclusively those who were
restratified to the HR group and thus received HAM, n  9:
100% vs 61%  7%, plogrank  0.05). There were only 2 inv(16)
patients in study 98 with  5% BM blasts on day 15 (both in
remission, treated with HAM).
WBC
High WBC count is of negative impact on outcome in adults with
t(8;21).10,20 However, this was not seen in our pediatric t(8;21)
patient cohort (EFS: WBC  20 000/L vs  20 000/L
 74%  5% vs 76%  8%, plogrank  0.82). There was also no
difference for patients with inv(16), EFS: WBC  20 000/L
vs  20 000/L  73%  10% vs 76%  6%, plogrank  0.83).
Additional cytogenetic aberrations and cooperating mutations
There is a remarkable association of t(8;21) and LOS, and
conflicting results have been reported in adults with LOS: a
somewhat better CR and better results in male patients with Y,2
but also an inferior outcome was reported.10 In our t(8;21) patients,
secondary cytogenetic abnormalities had a favorable effect com-
pared with patients with t(8;21) as sole aberration (EFS 78%  5%
vs 58%  8%, plogrank  0.06; supplemental Figure 2). This effect
was especially apparent in patients with LOS (EFS 83%  5% vs
64%  6%, plogrank  0.047). Patients with t(8;21) with additional
cytogenetic abnormalities showed a trend to benefit from reinduc-
tion with HAM (EFS 90%  4% vs 68%  11% in patients with a
sole t(8;21) abnormality, plogrank  0.07). In contrast, no differences
between these cytogenetic subgroups could be detected when
HAM was omitted (EFS 59%  10% vs 46%  12%,
plogrank  0.54). Patients with LOS showed a lower CIR (11%  4%
vs 34%  6%, p(Gray)  0.005) and higher EFS rates (83%  5%
Figure 4. Estimated probability of the cumulative incidence of relapse at 5
years in patients. (A) Patients with t(8;21). (B) Patients with inv(16). Treated with or
without HAM.
Figure 3. Estimated probability of 5-year EFS in patients. (A) Patients with t(8;21).
(B) Patients with inv(16). Treated with or without HAM.
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vs 64%  6%, plogrank  0.047) compared with others. The same
trend of improved outcome for patients with LOS was also seen in
the subgroups with or without HAM.
Trisomy 22 was the most common additional recurrent abnor-
mality in inv(16) and associated with better survival rates.21
However, in our series, EFS rates were similar for trisomy 22
patients compared with others (76%  16% vs 74%  6%,
plogrank  0.78).
One of 73 patients with (1) t(8;21) and 2 of 51 patients with
(2) inv(16) were FLT3-ITD–positive: (1) no event, and (2) 1 of
2 events. Nine of 36 (25%) patients with t(8;21) analyzed for c-KIT
mutations were c-KIT–positive (EFS 67%  9% vs 75%  15%,
plogrank  0.69). Only one of 24 patients with inv(16) proved to be
c-KIT–positive (no event).
Multivariate analysis
To confirm the effect of HAM in patients with t(8;21), we
performed a multivariate analysis using a Cox regression analysis
of EFS and relapse-free survival, including the following risk
factors: inv(16), t(8;21) without HAM (interaction term), age more
than or equal to 10 years, and BM blast count after induction
( 5%). Only t(8;21) without HAM treatment (EFS: hazard risk
ratio [RR]  2.83, 95% confidence interval, 1.33-6.02,
p(chi)  0.007; relapse-free survival: RR  3.82 [1.66-8.80],
p(chi)  0.002) was of prognostic significance.
Taken together, our results strongly support the notion that
CBF-AML patients with t(8;21), but not with inv(16), benefit from
reinduction with high-dose cytarabine and mitoxantrone on the
AML-BFM treatment protocol.
Discussion
Although it is clear that patients with CBF-AML have benefited
from intensification of AML treatment, it remains unclear which
components of the therapy have the most impact on this subtype
and whether patients with t(8,21) and inv(16) should be considered
as separated entities for treatment. Here we report, based on the
analysis of 2 large cohorts of CBF-AML patients, that omission of
reinduction with HAM resulted in a marked decrease in EFS for
patients with t(8;21). This provides conclusive evidence that
t(8;21) and inv(16) constitute distinct subtypes in the context of a
chemotherapy strategy that relies on HDAC. This observation is
consistent with previous reports from adult studies, suggesting that
t(8;21) patients had a less favorable outcome and a lower response
to salvage therapy than inv(16) patients.9,10,21
In the AML-BFM-1983 study, we identified 2 subtypes by
morphology that benefited most from intensified induction chemo-
therapy: patients with FAB M1/M2 with Auer rods and patients
with FAB M4Eo, which were shown retrospectively to include in
 80% of the patients with t(8;21) and inv(16).18 These observa-
tions indicate that the intensity of chemotherapy has a major impact
on the favorable outcome of CBF-AML. During the 1990s, studies
of the Cancer and Leukemia Group B (CALGB) in adults younger
than 60 years established HDAC (defined as 1 g/m2 per single
cytarabine dose) as an effective part of AML treatment.22 These
studies also suggested that patients with CBF leukemia benefit
most from an intensive post remission chemotherapy with 3 or 4
HDAC courses or hematopoietic stem cell transplantation.8,9
Analogical data for pediatric AML are scarce. A retrospective
analysis of patients with t(8;21) treated in the St Jude Children’s
Research Hospital between 1980 and 1996 revealed a relatively
poor outcome for this group of patients (6-year survival of
55%  9% and EFS of 33%  7%) on a treatment protocol in
which cytarabine was only used at a lower dose, never exceeding
500 mg/m2. The major difference in comparable studies with more
favorable outcome for this subgroup is the use of cytarabine at 1 to
3 g/m2.23 For example, the Japanese Childhood AML Cooperative
Study Group reported recently a 5-year survival of 86%  6% and
EFS of 71%  8% for low-risk patients, which mainly included
patients with t(8;21) on the AML99 trial.24 These patients were
treated with 5 consolidation courses, including cytarabine with a
dosage up to 3 g/m2. Similarly, the 7-year survival for CBF-AML
patients [18 patients with t(8;21) and 10 patients with inv(16)] on
the AML-93 trial of the Nordic Society for Paediatric Hematology
and Oncology was 77% 10%, using a regimen including 4 courses
of HDAC-based therapy.25 However, the dose-response relation-
ship between 1 and 3 g/m2 has not been well defined. A very recent
study of 860 adult patients younger than 60 years showed
comparable outcome when using cytarabine 1 g/m2 or up to 3 g/m2,
suggesting a plateau in the dose-response effect  1 g/m2.26 In this
study, there was no selective advantage for CBF-AML with 3 g/m2,
although the numbers were small. Taken together, our data and the
data reported in the literature indicate that higher doses of
cytarabine are a major component in the treatment regimen for
patients with CBF-AML.
Importantly, marked improvement of outcome for CBF-AML
has also been achieved by other treatment intensification ap-
proaches. In particular, treatment on the Medical Research Council
AML10 and AML12 trials, which have been based on high
cumulative doses of anthracyclines, but only one course with
HDAC, resulted in comparable outcome for CBF-AML, with a
10-year survival of 80% in 86 children with t(8;21) and 43 with
inv(16).3 In addition, the addition of gemtuzumab ozogamicin to
standard anthracycline-based chemotherapy was associated with
marked benefit for this group of patients in the adult Medical
Table 3. Results of patients with t(8;21) or inv(16) treated with or without HAM
t(8;21) inv(16)
HAM No HAM
P
HAM No HAM
Pn % n % n % n %
No. of patients 78 53 43 46
Nonresponders 0 0 3 6 .08 0 0 0 0
CR achieved 78 100 50 94 .24 43 98 46 100 .30
Death in CCR 2 3 1 2 .55 2 5 0 0 .14
Relapse (cumulative incidence) 14  4 34  7 .006 15  6 23  8 .44
Secondary malignancies 1 1 0 0 2 5 1 2
P (survival 5 y) 92  3 80  6 .047 93  4 94  4 .69
P (EFS 5 y) 84  4 59  7 .001 75  7 71  9 .95
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Research Council AML15 trial.27 As in many other instances, such
questions have to be evaluated in the context of each particular
chemotherapy backbone, but these results indicate that overall
treatment intensity, rather than a specific effect of cytarabine, is
critical for patients with t(8;21), a finding that is consistent with
findings in adults.9 On the other hand, specifically reinduction at an
early phase of treatment in combination with mitoxantrone was
required in our study to improve outcome. This observation and the
fact that patients with inv(16) have a comparably good outcome
without reinduction are new findings, which will be considered in
our future treatment regimen.
During the last years, it appeared that the day 15 blasts had no
impact on the outcome of patients with favorable karyotypes.28,29
Assessment of in vivo response to treatment at day 15 was not
sufficient to capture a group of patients with t(8;21) who would
benefit from more intensive treatment. Our results show that the
few patients with inferior response fared even better than those
with  5% blasts in study AML-BFM-2004, apparently because
they were treated with HAM, which is an additional finding
supporting the benefit of reinduction for this subtype.
Similarly, there is evidence that treatment intensity has to be
high also in subgroups of t(8;21) with additional cytogenetic
abnormalities who seem to have a favorable outcome, such as LOS.
Patients with t(8;21) and additional cytogenetic abnormalities did
show a trend for better outcome, which is consistent with similar
observations in adults,2,21 and they did appear to benefit as well
from reinduction therapy. Our data are consistent with previous
reports in adult cohorts, in which the incidence of secondary
cytogenetic aberrations was significantly higher in t(8;21) than in
inv(16) cases.9,21 Recurrent secondary aberrations appear to be
different in the 2 CBF-AML subgroups, including LOS and del(9q)
in t(8;21) cases and22 in inv(16) cases. It remains to be explored
to which extent distinct cooperative events may contribute to the
different phenotypes of t(8;21) and inv(16) cases in the context of
this treatment regimen. According to the data of our and other study
groups, the FLT3-ITD mutation, which was shown to be an
independent prognostic factor in the total group of AML patients,
does not appear to be associated more frequently with t(8;21).14,30
According to different authors, approximately one-third of adult
and pediatric CBF-AML patients show c-KIT mutations.30-32 This
is of potential therapeutic value as c-KIT mutations can be treated
with novel tyrosine kinase inhibitors. Recently, the CALGB group
reported an increased risk of relapse in adults presenting with c-KIT
mutations.32 However, this was not seen in another study with a
heterogeneous group of adult and pediatric patients where only a
trend was seen toward an increased risk of relapse for patients with
t(8;21) and c-KIT mutations.31 There was also no prognostic
significance of c-KIT in children with CBF leukemia,30 which was
confirmed in our study.
In conclusion, our results identified a marked biologic differ-
ence between the 2 subtypes of CBF-AML. The present analysis
has shown that HAM, an intensive combination of high-dose
cytarabine with mitoxantrone, given for second induction promotes
superior outcome for children with t(8;21) AML, but not for those
with inv(16). Using this strategy, a 5-year survival rate of  90%
can be achieved for these pediatric patients.
Acknowledgments
The authors thank the colleagues, data managers, and technicians
of the participating hospitals for their valuable cooperation,
Jans-Enno Mu¨ller for competent data management, and Gesche
Tallen and Ursula Bernsmann for their help in preparing the
manuscript.
This work was supported by the Deutsche Krebshilfe e.V. and
partly by the Czech Ministry of Education (grant MSM0021620813).
Authorship
Contribution: U.C., M.Z., J.-P.B., M.N.D., and D.R. designed and
performed research and wrote and edited the manuscript; M.Z.,
U.C., and D.R. analyzed the data; C.v.N., A. Sander, A.T.-S., and
S.C. performed diagnostic studies and edited the manuscript; and
A. Schrauder and J.S. provided study materials or patients and
edited the manuscript.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Ursula Creutzig, Klinik und Poliklinik fu¨r
Kinderheilkunde, Pa¨diatrische Ha¨matologie/Onkologie, Albert-
Schweitzer-Campus 1, D-48149 Mu¨nster, Germany; e-mail:
ursula@creutzig.de.
References
1. Grimwade D, Walker H, Oliver F, et al. The impor-
tance of diagnostic cytogenetics on outcome in
AML: analysis of 1612 patients entered into the
MRC AML 10 trial. The Medical Research Council
Adult and Children’s Leukaemia Working Parties.
Blood. 1998;92(7):2322-2333.
2. Grimwade D, Hills RK, Moorman AV, et al. Refine-
ment of cytogenetic classification in acute my-
eloid leukemia: determination of prognostic sig-
nificance of rare recurring chromosomal
abnormalities among 5876 younger adult patients
treated in the United Kingdom Medical Research
Council trials. Blood. 2010;116(3):354-365.
3. Harrison CJ, Hills RK, Moorman AV, et al. Cytoge-
netics of childhood acute myeloid leukemia:
United Kingdom Medical Research Council Treat-
ment trials AML 10 and 12. J Clin Oncol. 2010;
28(16):2674-2681.
4. von Neuhoff C, Reinhardt D, Sander A, et al.
Prognostic impact of specific chromosomal aber-
rations in a large group of pediatric patients with
acute myeloid leukemia treated uniformly accord-
ing to trial AML-BFM-1998. J Clin Oncol. 2010;
28(16):2682-2689.
5. Dombret H, Preudhomme C, Boissel N. Core
binding factor acute myeloid leukemia (CBF-
AML): is high-dose Ara-C (HDAC) consolidation
as effective as you think? Curr Opin Hematol.
2009;16(2):92-97.
6. Raimondi SC, Chang MN, Ravindranath Y, et al.
Chromosomal abnormalities in 478 children with
acute myeloid leukemia: clinical characteristics
and treatment outcome in a cooperative pediatric
oncology group study-POG 8821. Blood. 1999;
94(11):3707-3716.
7. Byrd JC, Mrozek K, Dodge RK, et al. Pretreat-
ment cytogenetic abnormalities are predictive of
induction success, cumulative incidence of re-
lapse, and overall survival in adult patients with
de novo acute myeloid leukemia: results from
Cancer and Leukemia Group B (CALGB 8461).
Blood. 2002;100(13):4325-4336.
8. Bloomfield CD, Lawrence D, Byrd JC, et al. Fre-
quency of prolonged remission duration after
high-dose cytarabine intensification in acute my-
eloid leukemia varies by cytogenetic subtype.
Cancer Res. 1998;58(18):4173-4179.
9. Marcucci G, Mrozek K, Ruppert AS, et al. Prog-
nostic factors and outcome of core binding factor
acute myeloid leukemia patients with t(8;21) differ
from those of patients with inv(16): a Cancer and
Leukemia Group B study. J Clin Oncol. 2005;
23(24):5705-5717.
10. Schlenk RF, Benner A, Krauter J, et al. Individual
patient data-based meta-analysis of patients
aged 16 to 60 years with core binding factor
acute myeloid leukemia: a survey of the German
Acute Myeloid Leukemia Intergroup. J Clin Oncol.
2004;22(18):3741-3750.
11. Creutzig U, Ritter J, Zimmermann M, et al. Im-
proved treatment results in high-risk pediatric
acute myeloid leukemia patients after intensifica-
tion with high-dose cytarabine and mitoxantrone:
results of Study Acute Myeloid Leukemia-Berlin-
Frankfurt-Munster 93. J Clin Oncol. 2001;19(10):
2705-2713.
12. Creutzig U, Zimmermann M, Lehrnbecher T, et al.
Less toxicity by optimizing chemotherapy, but not
by addition of granulocyte colony-stimulating fac-
tor in children and adolescents with acute my-
eloid leukemia: results of AML-BFM-1998. J Clin
Oncol. 2006;24(27):4499-4506.
5414 CREUTZIG et al BLOOD, 17 NOVEMBER 2011  VOLUME 118, NUMBER 20
 For personal use only. at Universitaet Zuerich on January 15, 2012. bloodjournal.hematologylibrary.orgFrom 
13. Creutzig U, Zimmermann M, Bourquin JP, et al.
CNS irradiation in pediatric acute myleoid leuke-
mia: equal results by 12 or 18 Gy in studies AML-
BFM98 and 2004. Pediatr Blood Cancer. 2011;
57(6):986-992.
14. Zwaan CM, Meshinchi S, Radich JP, et al. FLT3
internal tandem duplication in 234 children with
acute myeloid leukemia: prognostic significance
and relation to cellular drug resistance. Blood.
2003;102(7):2387-2394.
15. Cheson BD, Cassileth PA, Head DR, et al. Report
of the National Cancer Institute-sponsored work-
shop on definitions and response in acute my-
eloid leukemia. J Clin Oncol. 1990;8:813-819.
16. Kalbfleisch J, Prentice R. The Statistical Analysis
of Failure Time Data. New York, NY: Wiley; 2002.
17. Sander A, Zimmermann M, Dworzak M, et al.
Consequent and intensified relapse therapy im-
proved survival in pediatric AML: results of re-
lapse treatment in 379 patients of three consecu-
tive AML-BFM trials. Leukemia. 2010;24(8):1422-
1428.
18. Creutzig U, Zimmermann M, Ritter J, et al. Defini-
tion of a standard-risk group in children with AML.
Br J Haematol. 1999;104:630-639.
19. Wells RJ, Woods WG, Buckley JD, et al. Treat-
ment of newly diagnosed children and adoles-
cents with acute myeloid leukemia: a Children’s
Cancer Group study. J Clin Oncol. 1994;12(11):
2367-2377.
20. Prebet T, Boissel N, Reutenauer S, et al. Acute
myeloid leukemia with translocation (8;21) or in-
version (16) in elderly patients treated with con-
ventional chemotherapy: a collaborative study of
the French CBF-AML intergroup. J Clin Oncol.
2009;27(28):4747-4753.
21. Appelbaum FR, Kopecky KJ, Tallman MS, et al.
The clinical spectrum of adult acute myeloid leu-
kaemia associated with core binding factor trans-
locations. Br J Haematol. 2006;135(2):165-173.
22. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive
postremission chemotherapy in adults with acute
myeloid leukemia: Cancer and Leukemia Group
B. N Engl J Med. 1994;331(14):896-903.
23. Rubnitz JE, Raimondi SC, Halbert AR, et al.
Characteristics and outcome of t(8;21)-positive
childhood acute myeloid leukemia: a single insti-
tution’s experience. Leukemia. 2002;16(10):
2072-2077.
24. Tsukimoto I, Tawa A, Horibe K, et al. Risk-
stratified therapy and the intensive use of cytara-
bine improves the outcome in childhood acute
myeloid leukemia: the AML99 trial from the Japa-
nese Childhood AML Cooperative Study Group.
J Clin Oncol. 2009;27(24):4007-4013.
25. Lie SO, Abrahamsson J, Clausen N, et al. Treat-
ment stratification based on initial in vivo re-
sponse in acute myeloid leukaemia in children
without Down’s syndrome: results of NOPHO-
AML trials. Br J Haematol. 2003;122(2):217-225.
26. Lo¨wenberg B, Pabst T, Vellenga E, et al. Cytara-
bine dose for acute myeloid leukemia. N Engl
J Med. 2011;364(11):1027-1036.
27. Burnett AK, Hills RK, Milligan D, et al. Identifica-
tion of patients with acute myeloblastic leukemia
who benefit from the addition of gemtuzumab
ozogamicin: results of the MRC AML15 trial.
J Clin Oncol. 2011;29(4):369-377.
28. Creutzig U, Buchner T, Sauerland MC, et al. Sig-
nificance of age in acute myeloid leukemia pa-
tients younger than 30 years: a common analysis
of the pediatric trials AML-BFM 93/98 and the
adult trials AMLCG 92/99 and AMLSG HD93/98A.
Cancer. 2008;112(3):562-571.
29. Kern W, Haferlach T, Schoch C, et al. Early blast
clearance by remission induction therapy is a ma-
jor independent prognostic factor for both
achievement of complete remission and long-
term outcome in acute myeloid leukemia: data
from the German AML Cooperative Group (AM-
LCG) 1992 Trial. Blood. 2003;101(1):64-70.
30. Goemans BF, Zwaan CM, Miller M, et al. Muta-
tions in KIT and RAS are frequent events in pedi-
atric core-binding factor acute myeloid leukemia.
Leukemia. 2005;19(9):1536-1542.
31. Markova J, Markova J, Trnkova Z, et al. Monitor-
ing of minimal residual disease in patients with
core binding factor acute myeloid leukemia and
the impact of C-KIT, FLT3, and JAK2 mutations
on clinical outcome. Leuk Lymphoma. 2009;
50(9):1448-1460.
32. Paschka P, Marcucci G, Ruppert AS, et al. Ad-
verse prognostic significance of KIT mutations in
adult acute myeloid leukemia with inv(16) and
t(8;21): a Cancer and Leukemia Group B Study.
J Clin Oncol. 2006;24(24):3904-3911.
EFFICACY OF HAM IN t(8;21) OR inv(16) AML 5415BLOOD, 17 NOVEMBER 2011  VOLUME 118, NUMBER 20
 For personal use only. at Universitaet Zuerich on January 15, 2012. bloodjournal.hematologylibrary.orgFrom 
